{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:54:37Z","timestamp":1789638877762,"version":"4.0.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA","award":["NCT01165177"],"award-info":[{"award-number":["NCT01165177"]}]},{"name":"GlaxoSmithKline Biologicals SA","award":["NCT01165229"],"award-info":[{"award-number":["NCT01165229"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The assessments were integrated in two Phase III trials, ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229). HZ burden of illness and HZ burden of interference with activities of daily living were assessed by the Zoster Brief Pain Inventory (ZBPI) instrument and quality of life by the EuroQol-5 Dimension (EQ-5D) utility index and the SF-36 health survey. We report the ZOE-50 results and a pooled analysis of patients aged 70 years and older from the trials combined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The estimated vaccine efficacy in reducing HZ burden of illness and HZ burden of interference was greater than 90% in both the ZOE-50 and the pooled ZOE-70 analysis. In confirmed HZ cases, adjuvanted recombinant zoster vaccine reduced the maximal ZBPI worst-pain score in the pooled ZOE-70 analysis (p = .032) and the maximal ZBPI average-pain scores in both the ZOE-50 (p = .049) and the pooled ZOE-70 analysis (p = .043). In breakthrough HZ cases, trends for diminished loss of quality of life compared with placebo-recipient HZ cases were observed, with differences up to 0.14 on the EQ-5D index at time points during the 4 weeks following HZ onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjuvanted recombinant zoster vaccine reduced the HZ burden of illness significantly, particularly due to its very high vaccine efficacy in preventing HZ. For breakthrough HZ cases, the results suggest that the adjuvanted recombinant zoster vaccine mitigated severity of HZ-related pain, burden of interference with activities of daily living, and recipients\u2019 utility loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/gerona\/gly150","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T12:07:54Z","timestamp":1530101274000},"page":"1231-1238","source":"Crossref","is-referenced-by-count":59,"title":["Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older"],"prefix":"10.1093","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-0111","authenticated-orcid":false,"given":"Desmond","family":"Curran","sequence":"first","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Oostvogels","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Heineman","sequence":"additional","affiliation":[{"name":"GSK, King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Matthews","sequence":"additional","affiliation":[{"name":"Freelance, on behalf of GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"McElhaney","sequence":"additional","affiliation":[{"name":"Health Sciences North Research Institute, Sudbury, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"McNeil","sequence":"additional","affiliation":[{"name":"Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Diez-Domingo","sequence":"additional","affiliation":[{"name":"FISABIO-Public Health, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himal","family":"Lal","sequence":"additional","affiliation":[{"name":"GSK, King of Prussia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Andrews","sequence":"additional","affiliation":[{"name":"Diagnostics Research Group, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Athan","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Barwon Health, Deakin University, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Berglund","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Physics, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campora","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinandus","family":"de Looze","sequence":"additional","affiliation":[{"name":"AusTrials Pty Ltd, Sherwood, Queensland, Australia"},{"name":"School of Medicine, University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Korhonen","sequence":"additional","affiliation":[{"name":"Tampere Vaccine Research Clinic, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Leung","sequence":"additional","affiliation":[{"name":"United Christian Hospital, Kowloon, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"},{"name":"Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Volpi","sequence":"additional","affiliation":[{"name":"University of Rome Tor Vergata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Johnson","sequence":"additional","affiliation":[{"name":"University of Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ZOE-50\/70 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"2019071211155520400_CIT0001","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","article-title":"Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey","volume":"6","author":"Oster","year":"2005","journal-title":"J Pain"},{"key":"2019071211155520400_CIT0002","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10389-011-0481-8","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries","volume":"20","author":"Lukas","year":"2012","journal-title":"Z Gesundh Wiss"},{"key":"2019071211155520400_CIT0003","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40266-016-0389-7","article-title":"An algorithm for neuropathic pain management in older people","volume":"33","author":"Pickering","year":"2016","journal-title":"Drugs Aging"},{"key":"2019071211155520400_CIT0004","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1086\/421942","article-title":"Acute pain in herpes zoster and its impact on health-related quality of life","volume":"39","author":"Katz","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019071211155520400_CIT0005","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1503\/cmaj.091711","article-title":"The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study","volume":"182","author":"Drolet","year":"2010","journal-title":"CMAJ"},{"key":"2019071211155520400_CIT0006","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"2019071211155520400_CIT0007","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1128\/CMR.00052-13","article-title":"Pathogenesis and current approaches to control of varicella-zoster virus infections","volume":"26","author":"Gershon","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2019071211155520400_CIT0008","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/320169","article-title":"Herpes zoster in older adults","volume":"32","author":"Yoshikawa","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2019071211155520400_CIT0009","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/1471-2334-14-402","article-title":"Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study","volume":"14","author":"Gater","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2019071211155520400_CIT0010","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"2019071211155520400_CIT0011","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2019071211155520400_CIT0012","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2019071211155520400_CIT0013","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory","volume":"5","author":"Coplan","year":"2004","journal-title":"J Pain"},{"key":"2019071211155520400_CIT0014","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"2019071211155520400_CIT0015","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"Ware","year":"2000","journal-title":"Spine (Phila Pa 1976)"},{"key":"2019071211155520400_CIT0016","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1541-0420.2008.01131.x","article-title":"Chop-lump tests for vaccine trials","volume":"65","author":"Follmann","year":"2009","journal-title":"Biometrics"},{"key":"2019071211155520400_CIT0017","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"2019071211155520400_CIT0018","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/cid\/cir959","article-title":"A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals","volume":"54","author":"Ehrlich","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019071211155520400_CIT0019","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/oxfordjournals.aje.a118485","article-title":"Study in active immunization against pertussis","volume":"38","author":"Kendrick","year":"1939","journal-title":"Am J Hyg"},{"key":"2019071211155520400_CIT0020","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1097\/01.inf.0000197565.45345.4e","article-title":"Clinical trials of rotavirus vaccines in Europe","volume":"25","author":"Vesikari","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"2019071211155520400_CIT0021","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10389-010-0323-0","article-title":"Impact of herpes zoster and post-herpetic neuralgia on patients\u2019 quality of life: a patient-reported outcomes survey","volume":"18","author":"Weinke","year":"2010","journal-title":"Z Gesundh Wiss"},{"key":"2019071211155520400_CIT0022","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/00128071-200506050-00005","article-title":"Current management of herpes zoster: the European view","volume":"6","author":"Volpi","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"2019071211155520400_CIT0023","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"key":"2019071211155520400_CIT0024","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1478-7547-8-7","article-title":"A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK","volume":"8","author":"Moore","year":"2010","journal-title":"Cost Eff Resour Alloc"},{"key":"2019071211155520400_CIT0025","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.vaccine.2014.01.058","article-title":"Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review","volume":"32","author":"Kawai","year":"2014","journal-title":"Vaccine"},{"key":"2019071211155520400_CIT0026","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/cid\/ciq077","article-title":"Herpes zoster incidence among insured persons in the United States, 1993\u20132006: evaluation of impact of varicella vaccination","volume":"52","author":"Leung","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019071211155520400_CIT0027","doi-asserted-by":"publisher","first-page":"597","DOI":"10.22237\/jmasm\/1257035100","article-title":"New effect size rules of thumb","volume":"8","author":"Sawilowsky","year":"2009","journal-title":"J Mod App Stat Meth"}],"container-title":["The Journals of Gerontology: Series A"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/biomedgerontology\/article-pdf\/74\/8\/1231\/28931421\/gly150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T11:16:03Z","timestamp":1562930163000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biomedgerontology\/article\/74\/8\/1231\/5046047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,6,27]]},"published-print":{"date-parts":[[2019,7,12]]}},"URL":"https:\/\/doi.org\/10.1093\/gerona\/gly150","relation":{},"ISSN":["1079-5006","1758-535X"],"issn-type":[{"value":"1079-5006","type":"print"},{"value":"1758-535X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2018,6,27]]}}}